VitroGel™ is a ready-to-use, xeno-free tunable hydrogel system which closely mimics the natural extracellular matrix (ECM) environment.
VitroGel creates a functional and optimized environment to make cells feel like at home. The hydrogel system is room temperature stable, has a neutral pH, transparent, permeable and compatible with different imaging systems. The solution transforms into a tunable hydrogel matrix by simply mixing with cell culture medium. Cells cultured in this system can be easily harvested out with our VitroGel Cell Recovery Solution. The hydrogel can also be tuned to be injectable for in vivo studies.
From 2D coating, 3D culture to animal injection, VitroGel makes it possible to bridge the in vitro and in vivo studies with the same platform system.
VitroGel RGD-PLUS is a ready-to-use tunable hydrogel system modified with a high concentration of RGD cell adhesive peptide, promoting the cell attachment and cell-matrix interactions during the 3D cell culture. This hydrogel system has 3X RGD peptide compared to regular VitroGel 3D-RGD, which maintain a high level of integrin binding activities even after hydrogel dilution.
- Xeno-free tunable hydrogel modified with a high concentration of RGD peptide
- Support strong cell-cell communication; Good for adhesion cells or cells requiring stronger cell-matrix interactions
- Ready-to-use at room temperature
- Tunable hydrogel: dilute with VitroGel Dilution Solution (TYPE 1 or TYPE 2) for different concentrations
- Neutral pH
- Compatible with VitroGel Cell Recovery Solution for easy cell harvesting
- Injectable hydrogel (Check user handbook for preparation details)
- Ships room temperature. Store at 2-8 °C
- Size: 2 mL and 10 mL
- Number of uses (10 mL): 2-6 of 24-well plate at 250 to 300 µL/well
Documents and Resources
Data and References
3D culture of OP9 cells in both VitroGel 3D-RGD and VitroGel RGD-PLUS. (both hydrogels have been prepared at 1:3 dilution with VitroGel Dilution Solution (Type 1), The images were taken on day 2 and 7) VitroGel RGD-PLUS has better support for OP9 cell proliferation and cell-cell communication. The stronger cell-matrix interactions help the cells to form the cell-networking structure.
3D view of OP9 cells growth in VitroGel 3D-RGD and VitroGel RGD-PLUS. Cell networking structure formed in VitroGel RGD-PLUS and only single cell suspension has been observed in VitroGel 3D-RGD.
3D culture of U-87 MG cells in both VitroGel 3D-RGD and VitroGel RGD-PLUS. Cells can grow in 3D hydrogel at 1:1 and 1:3 dilution of both hydrogel. However, the morphologies of the 3D cell culture are very different. Unlike the spheroids structure in VitroGel 3D-RGD, U-87 MG cells perform better cell networking structure and the cell morphology in VitroGel RGD-PLUS indicates a better cell-cell and cell-matrix interaction.
Tables of successful cell types
|Cell types||Applications||Culture medium||Dilution|
|MCF-7 cells||2D and 3D culture||DMEM with 10% FBS||1:1 to 1:3|
|MCF-12A cells||3D culture||DMEM/F-12 with 10% FBS||1:3|
|MDA-MB-231 cells||3D culture||L-15 medium with 10% FBS||1:1 to 1:3|
|OP9 cells||2D and 3D culture||Alpha-MEM with 10% FBS||1:3|
|Panc-1 cells||2D and 3D culture||DMEM with 10% FBS||1:1 to 1:3|
|SF 268 cells||2D and 3D culture||RPMI 1640 with 10% FBS||1:1 to 1:3|
|SF 295 cells||2D and 3D culture||RPMI 1640 with 10% FBS||1:1 to 1:3|
|SNB 75 cells||2D and 3D culture||RPMI 1640 with 10% FBS||1:1 to 1:3|
|U-87 MG cells||2D and 3D culture||EMEM with 10% FBS||1:1 to 1:3|
|U-251 MG cells||2D and 3D culture||EMEM with 10% FBS||1:1 to 1:3|
- Powell K. Adding depth to cell culture. Science. American Association for the Advancement of Science; 2017;356: 96–98. doi:10.1126/science.356.6333.96
- Mahauad-Fernandez WD, Okeoma CM. B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells. Sci Rep. Nature Publishing Group; 2018;8: 4305. doi:10.1038/s41598-018-22364-z
- Mahauad-Fernandez WD, Naushad W, Panzner TD, Bashir A, Lal G, Okeoma CM. BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells. Sci Rep. Nature Publishing Group; 2018;8: 17608. doi:10.1038/s41598-018-35710-y
- Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. J Orthop Res. 2019;37: 510–521. doi:10.1002/jor.24189
- Hangzhan M, Nicole AS, Francis JH, Zhenfeng D. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. 2019;39: 182-193. doi:org/10.1016/j.ebiom.2018.12.022
- Seungwoo S, Jihye K, Je-Ryung L, Eun-chae J, Tae-Jin J, Wonhee L, YongKeun P. Enhancement of optical resolution in three-dimensional refractive-index tomograms of biological samples by employing micromirror-embedded coverslips. Lap Chip. 2018;18: 3484. doi: 10.1039/c8lc00880a
- Akamandisa MP, Nie K, Nahta R, Hambardzumyan D, Castellino RC. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. Neuro-oncology. 2019. doi:10.1093/neuonc/noz053